Business Advisory services                  Life Sciences Consulting                  Product Development                  ANDAs                  FTFs                  505 b 2 a                  Late Stage Assets                  Phase-II Trials                  Marketing Authorizationís                  Dossiers                  Site Transfers                  Scale ups                   Tail End Brands                  Technologies and Know-how                  Project Management                   Business Excellence & Six Sigma
Garphi was retained by a specialty pharmaceutical company seeking to determine the optimal development path and appropriate licensing terms for a development-stage molecule with potential in multiple indications and therapeutic areas.
Garphithrough another of its associates leveraged their proprietary R&D benchmarking methodology to collect and analyze historical drug development data for over 1900 clinical programs of interest from 1994-2008. R&D benchmarking data were combined with licensing and market metrics to prioritize 23 high-interest indications, according to their strategic and clinical attractiveness in the context of the companyís overall strategy.
  • R&D metrics included: probability of successful Phase II to Phase III transition, time in phase and historical
         licensing activity for each indication
  • Additional metrics for target markets included (among several others): size, competitive environment, un-met
         need, complexity of clinical trials and reimbursement landscape
  • Garphi also reviewed relevant comparable deals to determine the appropriate license structure and terms and to develop a framework for valuation. After an in-depth analysis Garphi and its associate recommended the optimal license structure for use in deal negotiations.